This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications …

Hematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant Histiocytosis+34 more

~Estimated

~$10 – $6,250

Mayo ClinicNCT06712810

International Rare Histiocytic Disorders Registry (IRHDR)

The rare histiocytic disorders (RHDs) are characterized by the infiltration of one or more organs by non-LCH histiocytes. They can range from localized disease…

Rare Histiocytic Disorders (RHDs)Erdheim-Chester Disease (ECD)Rosai-Dorfman Disease (RDD)+7 more

~Estimated

~$10 – $750

The Hospital for Sick ChildrenNCT02285582

Phase 2

Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib

The purpose of this Phase II clinical trial is to establish the safety and effectiveness of trametinib, a targeted therapy, for the treatment of newly or recen…

Langerhans Cell Histiocytosis

~Estimated

~$10 – $7,500

Cook Children's Health Care SystemNCT06582745

Phase 2

A Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib in Refractory Langerhans Cell Histiocytosis, LCH-Associated Neurodegenerative Disease, and Other Histiocytic Disorders.

This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorder…

Langerhan's Cell HistiocytosisJuvenile XanthogranulomaErdheim-Chester Disease+4 more

~Estimated

~$10 – $7,500

Carl AllenNCT04079179

← PreviousPage 2 of 2Next →